NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk

Novo Nordisk's real-world COMPETE SWITCH CV study found that type 2 diabetes patients escalating Ozempic to 2 mg had a statistically significant 6% lower observed risk of major adverse cardiovascular events versus patients switching to Eli Lilly's Mounjaro, including doses up to 15 mg. At 720 days, 36.9% of patients had escalated to Ozempic 2 mg, compared with 5.7% who switched to Mounjaro. The results support Ozempic's competitive cardiovascular profile, but are observational rather than causal and did not evaluate safety outcomes.

Analysis

The data point is more useful as a defensive-marketing tool for NVO than as a near-term prescription-share inflection. Treatment-switching cohorts are inherently selected: clinicians may retain more stable patients on semaglutide while moving inadequate responders to tirzepatide, and residual confounding can readily exceed a 6% relative outcome difference. Without event counts, baseline-risk balance, discontinuation rates, and an independent peer-reviewed analysis, this should not change LLY’s earnings power or formulary position.

Near term, NVO can use cardiovascular differentiation in payer negotiations and field messaging for higher-risk diabetes patients, potentially protecting realized net price and persistence rather than driving material unit acceleration. The more consequential 6-18 month question is whether comparative evidence changes guideline language or insurer step-therapy rules; that would favor NVO’s installed diabetes base but remains unlikely from company-sponsored observational evidence alone. LLY retains structural advantages where weight loss and glycemic efficacy determine physician choice, so the read-through to its obesity franchise is especially limited.

Consensus may overreact to a favorable headline because NVO has become a crowded turnaround candidate. The key asymmetric risk is a subsequent analysis showing adjustment sensitivity, safety imbalance, or no benefit in propensity-matched subgroups; that would undermine the promotional narrative while leaving NVO exposed to competitive pricing. Conversely, independent replication, payer-policy citations, or evidence of improving Ozempic persistence would be credible catalysts for multiple stabilization over the next one to three months.

Key Decisions for Investors

• Do not initiate a directional LLY short on this release; require evidence of formulary displacement, slower Mounjaro/TRx growth, or a cut to 2027 consensus revenue before treating cardiovascular positioning as financially material.
• Tactically add NVO only on confirmation that the market has not already repriced the claim: use a 1-3 month long NVO / short LLY pair at modest sizing, with upside from NVO multiple repair and downside hedged by GLP-1 category exposure. Exit if subsequent study detail fails to show robust matching/event counts or if NVO does not reiterate diabetes-volume and net-price guidance.
• Monitor quarterly U.S. prescription persistence, payer coverage changes, and NVO’s diabetes realized-price commentary. A measurable persistence improvement or formulary preference would justify increasing the NVO/LLY pair; absent those data, treat this as sentiment support rather than an earnings catalyst.
• Avoid PGEN and ACIU as read-through trades: their estimate revisions and trading performance are unrelated to the GLP-1 competitive mechanism and introduce idiosyncratic clinical-stage risk.